EHR-based Genomic Discovery and Implementation (Pediatric Participants Supplement)

$145,327U01FY2023HGNIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications & trials

Paper 39606329 Paper 39315247 Paper 39103647 Paper 39080328 Paper 39072039 Paper 38827078 Paper 38688278 Paper 38649760 Paper 38645167 Paper 38614075 Paper 38470993 Paper 38380516 Paper 38374346 Paper 38260403 Paper 38260263 Paper 38126226 Paper 38036523 Paper 37986758 Paper 37898691 Paper 37883979 Paper 37845353 Paper 37752310 Paper 37689782 Paper 37662324 Paper 37609230 Paper 37373918 Paper 37343562 Paper 37333246 Paper 37246632 Paper 37223852 Paper 37196047 Paper 37071725 Paper 36846987 Paper 36737471 Paper 36718804 Paper 36621880 Paper 36540998 Paper 36540997 Paper 36474423 Paper 36383166 Paper 36372681 Paper 36252120 Paper 36224396 Paper 36173399 Paper 35943490 Paper 35915156 Paper 35796859 Paper 35765100 Paper 35701404 Paper 35595084 Paper 35594287 Paper 35354965 Paper 35331649 Paper 35287515 Paper 35226188 Paper 35216901 Paper 35102242 Paper 35090449 Paper 35041929 Paper 34930020 Paper 34665896 Paper 34341450 Paper 34302027 Paper 34282949 Paper 34257418 Paper 34193479 Paper 34168341 Paper 34140684 Paper 34088418 Paper 34086673 Paper 33979874 Paper 33977795 Paper 33951936 Paper 33941608 Paper 33930535 Paper 33919001 Paper 33861317 Paper 33854068 Paper 33824501 Paper 33729212 Paper 33500569 Paper 33407432 Paper 33287626 Paper 33226870 Paper 32987879 Paper 32964493 Paper 32952152 Paper 32669678 Paper 32669677 Paper 32555418 Paper 32546831 Paper 32413979 Paper 32386537 Paper 32377377 Paper 32371921 Paper 32349224 Paper 32329251 Paper 32316380 Paper 32307929 Paper 32292118

Abstract

PROJECT SUMMARY In this supplemental application we propose to build on our work in eMERGE IV to recruit an additional 250 adolescents who will undergo genomic testing in a CLIA laboratory (Broad). Thus, the pediatric study cohort at Mayo will comprise a total of 350 adolescent participants attending the community pediatric and adolescent medicine clinic and local schools. We will estimate polygenic risk scores (PRSs) for 4 diseases that pose a significant public health burden including asthma, obesity, type 1 diabetes, and type 2 diabetes. DNA will be sent for CLIA-certified genomic testing, and we will calculate candidate loci or genome wide PRS using novel methods to adapt these to specific genetic ancestry groups. Validated PRS will be combined with family history and clinical risk scores to create comprehensive risk profiles that will be reported to participants and providers and placed in the electronic health record (EHR) with linkage to clinical decision support (CDS) that includes guideline-based risk-management information. For participants who are at significantly higher risk for developing at least 1 of the 4 diseases, results will be disclosed in-person followed by assessment of outcomes including new tests ordered, risk reduction measures, and changes in modifiable risk factors. Our focus on PRS brings genomic medicine to the population. Our specific aims include: 1) Recruit 250 additional adolescent participants (total n=350) who will undergo genomic testing for PRS in a CLIA laboratory; 2) Integrate PRS in the EHR with linkage to CDS that incorporates recommendations for healthcare providers and develop scalable methods for disclosing PRS results to participants; 3) Estimate PRS for 4 diseases in 350 adolescent participants and compute comprehensive risk profiles (that include PRS) for return to participants; 4) Assess outcomes following return of results.

View original record on NIH RePORTER →